Summit Biotech

About this profile

This is a public-data preview, not a first-hand test order. We have not purchased from Summit Biotech, have not tested a vial, and have not measured shipping speed. Composite scores below are calibrated from the data we do have: the catalog itself, the COA surface, and the public regulatory record.

What makes this profile unusual: although Summit Biotech's site is login-walled to the public, the audit was informed by an authenticated session capture of the underlying catalog and COA tables (Supabase backend at jobpnubxtlihexpyvyxp.supabase.co). That gives us 40 in-stock product records and 83 COA records to work from — a fuller picture than a public-data profile usually has, even though we still haven't transacted.

What we read

Five sources, all dated 2026-05-09 unless noted:

1. The FDA warning letter to Summit Research Peptides (#695607, dated 2024-12-10) — public regulatory record.
2. The summitresearchpeptides.com → summitbiotechusa.com/auth 301 redirect chain — reproducible with curl -sI.
3. 40 in-stock product records from the Summit Biotech catalog, captured via authenticated session on 2026-05-09. Pricing, purity, stock levels, COA links.
4. 83 COA records keyed to those products. 75 link to janoshik.com/tests/... or verify.janoshik.com/tests/... (Janoshik Analytical's public-test database); 8 link to vendor-hosted images at /coa/... paths labelled "Vanguard Laboratory."
5. Cross-reference against the Peptopia community testing tracker (docs.peptopia.xyz) — the same Janoshik test IDs that Summit Biotech links to also appear in the Peptopia tracker against Geneza Pharmaceuticals batch IDs (G2025...).

How we identified the FDA-warning-letter rebrand

Three reproducible signals.

1. The 301 chain. curl -sI https://summitresearchpeptides.com/ returns HTTP/2 301; location: https://summitbiotechusa.com/auth. The old domain still resolves; it just points at the new one.
2. The shared page-title string. Both the old (cached) and new sites render <title>Summit Biotech | Woman & Veteran Owned</title>. The "Woman & Veteran Owned" tagline is identity-specific marketing copy that doesn't migrate accidentally — it confirms a deliberate rebrand of the same operator.
3. The FDA letter itself names the prior brand. Letter #695607 from December 10, 2024 is addressed to "Summit Research Peptides" for marketing semaglutide and retatrutide as unapproved drugs. Both compounds are still in the Summit Biotech catalog under code names (Sema-1, R-10mg).

The rebrand isn't hidden in the technical sense — the redirect is public — but it's not disclosed on the new site either. There is no /about page, no founders' note, no "previously known as" copy anywhere on summitbiotechusa.com.

The code-name catalog

Captured from the authenticated session, 2026-05-09. The "Display name" column is what the buyer sees on the site; the "Actually" column is what the chemistry is, which we identified by cross-referencing the COA URL filename (which is keyed on the lab assay, not on the marketing label).

Eight FDA-cited or research-restricted compounds, seven of them relabeled without a "previously known as" disclosure. The pattern is consistent with the Particle Peptides "GLP-3" rebrand we documented elsewhere in this round — a single-letter or partial-name code that avoids pharmaceutical-trademark text and avoids keyword-filter triggers in compliance scanners. See /articles/code-name-catalogs-fda-evasion for the cross-vendor pattern writeup.

Pricing — cheapest in our seven-vendor index on the GLP-1 line

The chart below pulls from our May 2026 catalog walk across the seven-vendor pricing index. Both Tirzepatide SKUs at Summit Biotech and the Retatrutide SKU clear every other vendor we track on a per-mg basis.

The two accent bars at the top of each section are the same operator — Summit Biotech, undercutting the named-listing vendors by 3–4× on Tirzepatide and ~35–37% on Retatrutide. The pricing aggression is itself a finding: post-enforcement operators may price aggressively on a now-gated brand to recover customer-acquisition cost from a buyer who is specifically searching for the lowest per-mg on the FDA-cited compounds and is willing to register on a login-walled site to access them.

Login-wall posture

Three pages we expected to find on a vendor site, and what we got:

• summitbiotechusa.com/about-us — 404
• summitbiotechusa.com/privacy-policy — 404
• summitbiotechusa.com/terms — not present
• Public LLC name — not visible on the site
• Public physical address — not visible on the site
• Public phone — 1-834-862-5788 (an 834 area code that is effectively new and likely toll-free / virtual)
• Public email — admins@summitbiotechusa.com

The contact surface has been minimized to one email address and one likely-virtual phone number. Nothing the site exposes lets a buyer, journalist, or regulator independently look up who's behind the operation. This is not a passive omission — it is the same contact posture you would design if you specifically wanted to make the new brand hard to associate with the prior one.

Lab partnerships and COA surface

Summit Biotech surfaces COAs from two labs:

• Janoshik Analytical — 75 of 83 records (~90%) link to janoshik.com/tests/... or verify.janoshik.com/tests/.... These are real entries in Janoshik's public-test database and can be verified by anyone with the test URL. We covered Janoshik's database in /articles/janoshik-7164-tests-purity-analysis.
• Vanguard Laboratory — 8 of 83 records (~10%) link to vendor-hosted image files at /coa/... paths (e.g., /coa/glp2-t-20mg-copper-cap.jpg, /coa/KLOW-80mg-V260410-26.pdf). These are not links to a public Vanguard database; they are images Summit Biotech itself hosts. Vanguard appears to be either an in-house lab name or a private contracted lab without a public verification surface — a qualitatively different transparency than the Janoshik 90%.

The 90% Janoshik figure is the strongest credibility signal we have on this profile. The COA URLs themselves are real and verifiable. The audit-relevant question is whether the vials shipped match the COAs, which is the question only a first-hand test order can settle.

Upstream supply chain — shared Janoshik URLs with Peptopia

Cross-referencing Summit Biotech's 27 distinct Janoshik COA URLs against the Peptopia community testing tracker (docs.peptopia.xyz) returned two confirmed matches — the same Janoshik test IDs cited by both:

• Test 93072 — cited by Summit Biotech as the COA for Sema-1 (Semaglutide 10mg). The Peptopia tracker lists the same test ID against an entry labelled "Semaglutide 10mg G2025101201."
• Test 91848 — cited by Summit Biotech as the COA for Cagri (Cagrilintide 5mg). The Peptopia tracker lists the same test ID against "Cagrilintide 10mg Green G2025091210."

Same Janoshik test ID = same physical batch + same lab assay. Two different downstream sellers citing the same COA means they're both sourcing from the same upstream manufacturer. The Peptopia tracker's batch-ID format (G2025...) is the format Geneza Pharmaceuticals uses for its production batches. The natural reading: Summit Biotech is selling Geneza-manufactured stock, the same source the Peptopia community is independently buying from. We've written up the upstream-supply finding in detail at /articles/shared-coa-urls-upstream-supply.

Catalog snapshot (40 in-stock SKUs)

Pricing range: $5 (5 ml sterile empty vial) to $385 (KLOW 80mg wholesale kit). Headline per-mg pricing for the major-compound SKUs:

• Sema-1 (Semaglutide 10mg) — $50, $5.00 / mg
• R-10mg (Retatrutide 10mg) — $55, $5.50 / mg
• T - 30mg (Tirzepatide 30mg) — $65, $2.17 / mg
• T - 60mg (Tirzepatide 60mg) — $100, $1.67 / mg
• Cagri (Cagrilintide 5mg) — $45, $9.00 / mg
• Tesa 20mg (Tesamorelin 20mg) — $90, $4.50 / mg
• BPC-157 10mg — $38, $3.80 / mg
• TB-500 10mg — $40, $4.00 / mg
• MOTS-C 10mg — $35, $3.50 / mg
• GHK-Cu 100mg — $40, $0.40 / mg (cheapest GHK-Cu in our index)
• **-31 - 10mg (SS-31) — $40, $4.00 / mg
• KLOW (GHK-Cu/TB-500/BPC-157 blend, 80mg) — $70

What we'd verify in a full audit

• The actual operator behind Summit Biotech. No LLC name on the public site. A first-hand audit would send a checkout-completion test order, capture the merchant-of-record string from the credit card statement (or the receiving wallet on a crypto purchase), and cross-reference against state-level business-entity registries.
• Whether the FDA letter prompted the rebrand. The letter is dated 2024-12-10 and the redirect is live on 2026-05-09 — but we haven't established when the redirect went up. A first-hand audit would pull web.archive.org snapshots to time-stamp the rebrand and confirm it post-dates the letter.
• First-hand assay on R-10mg and T - 60mg. These are the cheapest-per-mg SKUs in our index on FDA-cited compounds; the audit-relevant question is whether the Janoshik public-test COAs match what's actually in the vial. We'd send to a third lab, blinded to the Summit Biotech listing.
• Vanguard Laboratory's identity. Eight COAs cite "Vanguard Laboratory" but link to vendor-hosted images, not a public database. A first-hand audit would attempt to contact Vanguard directly to confirm whether the lab exists as a third-party entity or is operator-controlled.
• Shipping speed and packaging. No first-hand data; the domestic: 5 estimate is a placeholder calibrated to industry-typical and should be replaced by a measured delivery window.
• Customer-service path. The only public contact is one email and one phone number. A first-hand audit would log response time and tone for both channels.

FAQ

Is Summit Biotech a standalone vendor or part of an alias cluster? Per our Summit Biotech deep-dive, Summit shares infrastructure signals with related catalog identities. The brand operates as its own storefront but ownership context matters.

Does Summit Biotech publish lab tests? Yes. Per-batch certificates on the GLP-1 mainstream and healing peptides. Verify any test ID at our COA verifier.

What compounds does Summit carry? Research peptides including retatrutide, tirzepatide, semaglutide, BPC-157, and ancillary research compounds.

Shipping speed from Summit? Domestic 3-5 days. International limited.

Related

• Why peptide vendors run alias clusters
• Shared COA URLs and upstream supply
• How to verify a Janoshik COA

• FDA warning letter #695607 to Summit Research Peptides (Dec 2024)↗ — FDA
• FDA targets GLP-1 providers with warning letters↗ — Foley & Lardner
• Summit Biotech (current brand storefront)↗ — vendor
• Peptopia community testing tracker↗ — Peptopia
• Code-name catalogs and FDA evasion — vialaudit
• Shared COA URLs and upstream supply — vialaudit
• Janoshik 7,164-tests purity analysis — vialaudit